Targets › IFNA1
4 programs from 4 companies in 4 trials: 2 Phase 1, 1 Phase 3, 1 Phase 4; Infectious disease, Oncology; next expected readout Dec 2026.
Produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase. (UniProt, P0DY56)
Open in Phaseline: the race on IFNA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| First Affiliated Hospital of Wenzhou Medical University | Peg-Interferon α Type I interferon receptor agonist with antiviral and immunomodulatory activity | IFNA1 | Phase 4 | Nonalcoholic Fatty Liver Disease | Dec 2028 |
| Kexing Biopharm | Human interferon α1b Inhalation Solution Interferon alpha-1b, antiviral cytokine | IFNA1 | Phase 3 | Respiratory Syncytial Virus Infections | Jun 2027 |
| Chinese PLA General Hospital | MSC-IFNα Interferon alpha-expressing mesenchymal stromal cells | IFNA1 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Dec 2026 |
| University of Utah | Pegylated interferon alpha2a Type I interferon receptor agonist | IFNA1 | Phase 1 | Myelofibrosis | Jan 2027 |
Respiratory Syncytial Virus Infections (1) Myelofibrosis (1) Locally Advanced or Metastatic Solid Tumors (1) Nonalcoholic Fatty Liver Disease (1)
protein or peptide (3), mixed (1)
Kexing Biopharm (1) University of Utah (1) Chinese PLA General Hospital (1) First Affiliated Hospital of Wenzhou Medical University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.